Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population

Background: Adalimumab is an antitumor necrosis factor agent approved by the U.S. Food and Drug Administration in 2002 for the treatment of various rheumatologic diseases. Recent approval of adalimumab biosimilars presents an important area of study to determine real-world efficacy and cost savings of biosimilars. Obje...

S. Delprete, Krista Dessureault, Molly Bachman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.